Alzheimer’s disease

Subcellular Biochemistry

Volumn 65, Issue , 2012, Pages 329-352

  De Paula, Vanessa J ^a   Radanovic, Marcia ^a   Diniz, Breno S ^a   Forlenza, Orestes V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer s disease amyloid precursor; Neuritic plaques; Neurofibrillary tangles; Protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; SECRETASE;

AGING; ALZHEIMER DISEASE; ANIMAL; BRAIN LEVEL; CHEMISTRY; GENETICS; HUMAN; METABOLISM; NEOCORTEX; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN CHEMISTRY; HUMANS; NEOCORTEX; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84883137463     PISSN: 03060225     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-5416-4_14     Document Type: Article

References (134)

1. Aizenstein HJ, Nebes RD, Saxton JA, Price J, Mathis C, Tsopelas ND, Ziolko SK, James J, Snitz B, Houck PR (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509-1517
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:270-279
3. Anandatheerthavarada HK, Biswas GM, RobinAN,AvadhaniG (2003) Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161:41-54
4. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H,Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58:373-379
5. Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, Matsui T, MorikawaY, Horikawa E, Kohno H (2000) CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 166:201-203
6. Bates KA, Verdile G, Li Q, Ames D, Hudson P, Masters C (2009) Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 14:469-486
7. Bennett DA, Schneider JA, Bienias JL, Evans DA,Wilson RS (2005) Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64:834-841
8. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66:1837-1844
9. BlennowK (2004) Cerebrospinal fluid protein biomarkers forAlzheimer's disease. NeuroRX 1:213- 225
10. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2:605-613
11. Blennow K, Hampel H,Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131-144
12. Bouwman FH, Schoonenboom SN,Van Der FlierWM,Van Elk EJ, Kok A, Barkhof F, Blankenstein MA, Scheltens P (2007) CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 28:1070-1074
13. Braak H, Braak E (1998) Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 53:127-140
14. Braak H, Tredici KD (2004) Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-b formation. Neurobiol Aging 25:713-718
15. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Ann Rev Neurosci 31:175-193
16. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95-130
17. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129:3035-3041
18. Buxbaum JD, Thinakaran G, Koliatsos V, O'Callahan J, Slunt HH, Price DL, Sisodia SS (1998) Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci 18:9629-9637
19. Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, Barakos J (2011) Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 7:396-401
20. Chang WP, Koelsch G, Wong S, Downs D, Da H, Weerasena V, Gordon B, Devasamudram T, Bilcer G, Ghosh AK, Tang J (2004) In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 89:1409-1416
21. Choi SR, Golding G, Zhuang Z, ZhangW, Lim N, Hefti F (2009) Preclinical properties of 18F-AV- 45: a PET agent for Abeta plaques in the brain. J Nucl Med 50:1887-1894
22. Citron M (2010) Alzheimer's disease: strategies for disease modification. Nature Rev Drug Discov 9:387-398
23. Clark C, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris J, McKeel DW, Farlow M, Weitlauf SL (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60:1696-1702
24. ClevelandDW, Hoffman PN (1991) Neuronal and glial cytoskeletons. Curr. Opin. Neurobiol 1:346- 353
25. Consensus Report of theWorking Group on: "Molecular and Biochemical Markers of Alzheimer's Disease" (1998) The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on AgingWorking Group. Neurobiol Aging 19:109-116
26. Cummings J (2006) Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimer Dement 2:263-271
27. De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gammasecretase complex. Neuron 38:9-12
28. Diniz B, Pinto J, Forlenza OV (2008) Do CSF total tau, phosphorylated tau, and b-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease?Asystematic review and meta-analysis of the literature.World J Biol Psychiatry 9:172-182
29. Drechsel DN, Hyman AA, Cobb MH, KirschnerMW (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3:1141-1154
30. Eckman CB, Eckman EA (2007) An Update on the amyloid hypothesis. Neurol Clin 25:669-682
31. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, TaiYF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68:501-508
32. FaganAM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59:512-519
33. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris J, Holtzman D (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64:343-349
34. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1:371-380
35. Fellgiebel A, Siessmeier T, Scheurich A, Winterer G, Bartenstein P, Schmidt LG, Möller MJ (2004) Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy- D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry 56:279-283
36. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65:1031-1038
37. ForlenzaOV, Diniz BS, GattazWF (2010a) Diagnosis and biomarkers of predementia inAlzheimer's disease. BMC Med 8:89
38. Forlenza OV, Diniz BS, Talib LL, Radanovic M, Yassuda MS, Ojopi EB, Gattaz WF (2010b) Clinical and biological predictors ofAlzheimer's disease in patients with amnestic mild cognitive impairment. Rev Bras Psiquiatr 32:216-222
39. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langström B, Nordberg A (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456-1465
40. Funato H, Yoshimura M, Kusui K, Tamaoka A, Ishikawa K, Ohkoshi N, Namekata K, Okeda R, IharaY (1998) Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. Am J Pathol 152:1633-1640
41. Geylis V, Steinitz M (2006) Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev 5:33-39
42. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby. L, Rovira MB, Forette F, Orgogozo JM (2005) AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553-1562
43. Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890
44. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH (2009) Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302:2557-2564
45. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M (2004) Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9:705-710
46. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228-234
47. Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S (2009) Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 30:165-173
48. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185
49. Hernández F, Avila J (2007) Tauopathies. Cell Mol Life Sci 64:2219-2233
50. Holmes C, Boche D,Wilkinson D,Yadegarfar G, HopkinsV, Bayer. A, JonesRW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JAR (2008) Long-term effects ofAb42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-223
51. Hye A, Kerr F, Archer N, Foy C, Poppe M, Brown R, Hamilton G, Powell J, Anderton B, Lovestone S (2005) Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett 373:1-4
52. Imbimbo BP, Del Giudice. E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G, Facchinetti F,Volta R, PietriniV, Baroc MF, Serneels L, De Strooper B, LeonA (2007) 1-(3′,4′-Dichloro-2- fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp. Ther 323:822-830
53. Iqbal K, Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimuk H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 13:198-210
54. Jack CR, Lowe V, Weigand S, Wiste H, Senjem M, Knopman DS, Shiung M, Gunter J, Boeve B, Kemp B (2009a) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132:1355-1365
55. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS,WeinerMW (2009b) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9:119-128
56. Johnson GV, StoothoffWH (2004) Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 117:5721-9
57. Josephs K, Whitwell J, Ahmed Z, Shiung M,Weigand S, Knopman D, Boeve B, Parisi J, Petersen R, Dickson D et al (2008) β-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63:204-212
58. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Müller-Hill B (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736
59. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Brack A, Oikonen V, Kailajδrvi M, Scheinin M, Viitanen M et al (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603-1606
60. Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist. G, Holt DP, Bergstrϕm M, Savitcheva I, Huang GF, Estrada S et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55:306-319
61. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC (2003) Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62:1087-1095
62. Kosik KS (1993) The molecular and cellular biology fo tau. Brain Path 3:39-43
63. Kulandaivelu SV, Gopal T (2006) Amyloidogenic processing of b-amyloid precursor protein in intracellular compartments. Neurology 66: S69-S73
64. Lahiri DK, Chen D, Maloney B, Holloway HW, Yu QS, Utsuki T, Giordano T, Sambamurti K, Greig NH (2007) The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 320:386-396
65. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96:3922-3927
66. Lesne S, Kotilinek L (2005) Amyloid plaques and amyloid-b oligomers: an ongoing debate. J Neurosci 25:9319-9320
67. Levy-Lahad E, Wasco W, Poorkaj P et al (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269:973-977
68. Lindwall G, Cole RD (1984) Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 259:5301-5305
69. Lippa CF, Morris JC (2006) Alzheimer neuropathology in nondemented aging: keeping mind over matter. Neurology 66:1801-1802
70. Lovestone S, Anderton B (1992) Cytoskeletal abnormalities in Alzheimer's disease. Curr Opin Neurol Neurosurg 5:883-888
71. Lovestone S, Hartley CL, Pearce J, Anderton BH (1997) The psosphorylation of tau: a critiacal stage in neurodevelopmental and neurodegenerative processes. Neuroscience 78:309-324
72. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD,Wekstein DR (2006) Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63:38-46
73. Mathis C, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk W (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740-2754
74. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385-393
75. Mattsson N, Blennow. K, Zetterberg H (2010) Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem Lab Med 48:603-607
76. Mattsson N,Andreasson U, Persson S, Arai. H, Batish SD, Bernardini S et al (2011) TheAlzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7:386-95
77. Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nature Rev Drug Discov 6:464-479
78. McKhannGM,Drachman D, Folstein M, Katzman R, Price D, StadlanEM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944
79. McKhann GM, Knopman DS, Chertkow H, Hyman. BT, Jack CR Jr, Kawas CH, Klunk WE, KoroshetzWJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, RossorMN,Scheltens P, Carrillo MC, Thies B,Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263-269
80. Mesulam M-M (2000) Aging, Alzheimer's Disease, and Dementia. Clinical and neuropathological perspectives. In: Mesulam M-M (ed) Principles of Behavioral and Cognitive Neurology, 2nd edn. Oxford University, NewYork
81. Mirra SS, HeymanA,McKeel D, Sumi SM, Crain BJ, Brownlee LM,Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479-486
82. Mohajeri MH (2008) Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 104:859-874
83. Moller HJ, Graeber MB (1998) The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 248:111-122
84. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982- 985
85. Morishima-Kawashima M, Oshima N, Ogata H,Yamaguchi H,Yoshimura M, Sugihara S, IharaY (2000) Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol 157:2093-2099
86. Murrell J, Farlow M, Ghetti B, Benson MD (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254:97-99
87. National Institute of Aging/Alzheimer's Association guidelines for the Neuropathological Assessment of AD (2011) http://www.alz.org/ documents. Accessed 17 Sept 2011
88. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nature Med 9:448-452
89. Oide T, Kinoshita T, Arima K (2006) Regression stage senile plaques in the natural course of Alzheimer's disease. Neuropathol Appl Neurobiol 32:539-556
90. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73:754-760
91. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46-54
92. Panza F, Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Vendemiale G, Capurso A, Imbimbo BP (2009) Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 26:537-555
93. Peskind ER, Ge LI, Shofer J, Quinn JF, Kaye JA,2006 Time will be of the essence in treating Alzheimer disease. JAMA 296:327-329
94. Petot GJ, Friedland RP (2004) Lipids, diet and Alzheimer disease: an extended summary. J Neurol Sci 226:31-33
95. Recuero M, Serrano E, Bullido MJ,Valdivieso F (2004) Abeta production as consequence of cellular death of a human neuroblastoma overexpressing APP. FEBS Lett 3:114-118
96. Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310:173-186
97. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB et al (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106:6820-6825
98. Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA (2010) Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67:353-364
99. Resnick SM, Sojkova J, ZhouY, AnY,YeW, Holt DP, Dannals RF, Mathis C, KlunkW, Ferrucci L et al (2010) Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 74:807-815
100. Rhein V, Eckert A (2007) Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function-role of glucose metabolism and insulin signalling. Arch Physiol Biochem 113:131-141
101. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59:1729-1734
102. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, KlunkWE, Mathis CA, BlennowK, Barakos J, Okello AA, Rodriguez MLS, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363-372
103. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI (1994) Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiat 57:419-425
104. Roe CM, Xiong C, Miller JP, Morris JC (2007) Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology 68:223-228
105. Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG (2011) Neuropathology and amyloid-b spectrum in a bapineuzumab immunotherapy recipient. JAlzheimers Dis 24:315-325
106. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G et al (2008) Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129-135
107. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab (2009) 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73:2061-2070
108. 2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE 3:e2718
109. Scarmeas N, SternY (2003) Cognitive reserve and lifestyle. J Clin Exp Neuropsychol 25:625-633
110. Schmitt HP (2006) Protein ubiquitination, degradation and the proteasome in neuro-degenerative disorders: No clear evidence for a significant pathogenetic role of proteasome failure in Alzheimer disease and related disorders. Medical Hypotheses 1:311-317
111. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA (2009a) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 18:691-701
112. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009b) Mixed pathologies in probable Alzheimer's disease and mild cognitive impairment. Ann Neurol 66:200-208
113. Selkoe DJ (1991) Amyloid protein and Alzheimer's disease. Sci Am 265:68-71, 74-76, 78
114. Serrano-PozoA,William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, FroschMP, HymanBT (2010) Beneficial effect of human anti-amyloidbeta active immunization on neurite morphology and tau pathology. Brain 133:1312-1327
115. Shahani N, Brandt R (2002) Functions and malfunctions of the tau proteins. Cell Mol Life Sci 39:1668-1680
116. Shaw L, Vanderstichele H, Knapik-Czajka M, Clark C, Aisen P, Petersen R, Blennow K, Soares H, Simon A, Lewczuk P et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65:403-413
117. Sherrington R, Rogaev EI, Liang Y et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754-760
118. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66:602-604
119. Small GW, KepeV, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, BurggrenAC, Cole GM, Vinters H et al (2006) PET of brain amyloid and tau in mild cognitive impairment. New Engl J Med 355:2652-2663
120. Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, Craft S, Leverenz JB, Montine TJ (2007) Pathological correlates of dementia in a longitudinal, population based sample of aging. Ann Neurol 62:406-413
121. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, FaganAM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, SternY,Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M,WagsterMV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:280-292
122. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH et al (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289:2094-2103
123. Swerdlow RH (2007a) Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? Neurobiol Aging 28:1465-1480
124. Swerdlow RH (2007b) Pathogenesis of Alzheimer's disease. Clin Interv Aging 2:347-359
125. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66:382-389
126. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of Abeta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791-1800
127. Trojanowski JQ, Lee VM, Dawbarn D, Allen SJ (1994) The kinase connection in Paired helical filament tau inAlzheimer's disease. Neurobiology ofAlzheimer's disease.AmJ Pathol 144:449- 453
128. Tupler LA, Krishnan KR, Greenberg DL, Marcovina SM, Payne ME, MacFall JR, Charles HC, Doraiswamy PM (2007) Predicting memory decline in normal elderly: genetics, MRI, and cognitive reserve. Neurobiol Aging 28:1644-1656
129. Vieira MN, Forny-Germano L, Saraiva LM, Sebollela A, Martinez AM, Houzel JC, De Felice FG, Ferreira ST (2007) Soluble oligomers from a non-disease related protein mimic Abeta-induced tau hyperphosphorylation and neurodegeneration. J Neurochem 103:736-48
130. Villemagne V, Pike KE, Darby D, Maruff P, Savage G, Ackermann U, Cowie TF, Currie, J, Chan, SG et al (2008) Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46:1688-1697
131. Wagner JA (2009) Biomarkers: principles, policies, and practice. Clin Pharmacol Ther 86:3-7
132. Wang JZ, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25:59-68
133. Wilson RS, Mendes de LeonCF, Barnes LL, Schneider JA, Bienias JL, EvansDA, BennettDA (2002) Participation in cognitively stimulating activities and risk of incident AD. JAMA 287:742-748
134. Wiltfang J, Lewczuk P, Riederer P, Granblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D et al (2005) Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia.World J Biol Psychiatry 6:69-84